Eton Pharmaceuticals (NASDAQ:ETON) Hits New 52-Week High – What’s Next?

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) shares reached a new 52-week high during trading on Monday . The stock traded as high as $32.51 and last traded at $32.49, with a volume of 402805 shares traded. The stock had previously closed at $30.26.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. B. Riley Financial lifted their target price on Eton Pharmaceuticals from $26.00 to $31.00 and gave the company a “buy” rating in a report on Friday, March 20th. HC Wainwright upped their price objective on Eton Pharmaceuticals from $52.00 to $57.00 and gave the stock a “buy” rating in a research report on Friday. Weiss Ratings reissued a “sell (d-)” rating on shares of Eton Pharmaceuticals in a report on Tuesday, April 21st. Craig Hallum upped their price objective on Eton Pharmaceuticals from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Friday, March 20th. Finally, Wall Street Zen raised Eton Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, March 21st. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Eton Pharmaceuticals currently has an average rating of “Hold” and an average target price of $41.00.

Eton Pharmaceuticals Trading Up 7.4%

The company has a 50 day simple moving average of $24.18 and a 200 day simple moving average of $19.22. The company has a current ratio of 1.21, a quick ratio of 0.88 and a debt-to-equity ratio of 0.62. The stock has a market capitalization of $889.90 million, a PE ratio of -464.08 and a beta of 0.82.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its quarterly earnings data on Thursday, May 14th. The company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.05). Eton Pharmaceuticals had a negative net margin of 1.70% and a negative return on equity of 5.68%. The company had revenue of $24.27 million for the quarter, compared to analysts’ expectations of $22.31 million. Analysts predict that Eton Pharmaceuticals, Inc. will post 0.82 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Eton Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in ETON. State of Alaska Department of Revenue acquired a new position in Eton Pharmaceuticals during the 3rd quarter worth approximately $30,000. Quarry LP acquired a new position in Eton Pharmaceuticals during the 3rd quarter worth approximately $37,000. Legal & General Group Plc acquired a new position in Eton Pharmaceuticals during the 2nd quarter worth approximately $41,000. Caitong International Asset Management Co. Ltd acquired a new position in Eton Pharmaceuticals during the 4th quarter worth approximately $44,000. Finally, China Universal Asset Management Co. Ltd. acquired a new position in Eton Pharmaceuticals during the 4th quarter worth approximately $74,000. Institutional investors and hedge funds own 27.86% of the company’s stock.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.